XML 44 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business (Details)
$ in Thousands
3 Months Ended
Mar. 19, 2020
Mar. 18, 2020
shares
Sep. 30, 2020
USD ($)
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Conversion of Stock [Line Items]          
Stock conversion ratio   0.1111      
Common stock, outstanding shares (in shares)   8,292,803   8,357,391 8,305,269
Cash and cash equivalents | $       $ 94,809 $ 98,679
Series A redeemable convertible preferred stock          
Conversion of Stock [Line Items]          
Stock conversion ratio   0.0873621142      
Series B redeemable convertible preferred stock          
Conversion of Stock [Line Items]          
Stock conversion ratio   0.1996348626      
Private Lumos Stockholders          
Conversion of Stock [Line Items]          
Aggregate shares received (in shares)   2,968,465      
Private Lumos Stockholders | NewLink Genetics          
Conversion of Stock [Line Items]          
Ownership percentage after transaction 0.50        
Former Stockholders          
Conversion of Stock [Line Items]          
Ownership percentage after transaction 0.50        
Merck | Held-for-sale or Disposed of by Sale | PRV Transfer Agreement | License and Collaborative Arrangement          
Conversion of Stock [Line Items]          
Cash from sale | $     $ 34,000    
Common Stock          
Conversion of Stock [Line Items]          
Stock conversion ratio   0.1308319305      
Common Stock | Private Lumos Stockholders          
Conversion of Stock [Line Items]          
Aggregate shares received (in shares)   4,146,398